Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

September 30, 2002

Primary Completion Date

February 28, 2007

Study Completion Date

December 31, 2009

Conditions
Prolymphocytic Leukemia
Interventions
BIOLOGICAL

alemtuzumab

DRUG

cyclophosphamide

DRUG

fludarabine phosphate

DRUG

mitoxantrone hydrochloride

Trial Locations (19)

29223

Allgemeinen Krankenhaus Celle Kinderklinik, Celle

41239

Haematologische Praxis - Moenchengladbach, Mönchengladbach

49074

Gemeinschaftliche Schwerpunktpraxis - Osnabrueck, Osnabrück

66113

Schwerpunktpraxis fuer Haematologie und Onkologie, Saarbrücken

71638

Internistische Praxis - Ludwigsburg, Ludwigsburg

95032

Sana Klinikum Hof, Hof

97070

Hamatologisch - Onkologische Praxis Wurzburg, Würzburg

A-1090

Allgemeines Krankenhaus - Universitatskliniken, Vienna

A-1140

Hanuschkrankenhaus, Vienna

D-47166

St. Johannes Hospital - Medical Klinik II, Duisburg

D-99089

Helios Klinikum Erfurt, Erfurt

D-45147

Universitaetsklinikum Essen, Essen

N 82467

Klinikum Garmisch - Partenkirchen GmbH, Garmisch-Partenkirchen

D-24116

University Hospital Schleswig-Holstein - Kiel Campus, Kiel

D-23560

Sana Kliniken Luebeck, Lübeck

D-66113

Caritasklinik St. Theresia, Saarbrücken

D-72076

Southwest German Cancer Center at Eberhard-Karls-University, Tübingen

D-65199

Dr. Horst-Schmidt-Kliniken, Wiesbaden

02763

Klinikum des Landkreises Loebau-Zittau GmbH, Zittau

All Listed Sponsors
lead

German CLL Study Group

OTHER

NCT00278213 - Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia | Biotech Hunter | Biotech Hunter